Three Companies Grant Inducement Equity Awards
Three Companies Grant Inducement Equity Awards
Anonymous
Key Points
1
EyePoint’s options were granted outside its 2023 Long-Term Incentive Plan and were approved by the company’s Compensation Committee as material to the employee’s decision to join EyePoint. The award vests 25% on the first anniversary of the grant date, with the balance vesting in equal monthly installments over the following three years, subject to continued service.
2
vTv Therapeutics’ options are governed by the company’s 2026 Inducement Plan and the related stock-option agreement; after the initial 25% vesting at one year, the remaining shares vest quarterly over the next 36 months, contingent on continued employment.
3
vTv described cadisegliatin as a liver-selective glucokinase activator that increases glucokinase activity independently of insulin in nonclinical studies; the company is testing it as a potential first-in-class oral adjunctive treatment for type 1 diabetes in a U.S. Phase 3 trial.
4
Health Catalyst said its inducement plan is reserved for people who were not previously employees or directors of the company or its subsidiaries, or who are joining after a bona fide period of non-employment, consistent with Nasdaq Listing Rule 5635(c)(4).
5
Kohl’s 59,000 open-market purchases took place over two dates—September 11 and September 14, 2026—and had a reported weighted average price of $1.787188 per share.
Three healthcare and life sciences companies granted inducement equity awards to new and existing employees in September 2026. EyePoint Pharmaceuticals awarded options for 3,000 shares to a new hire, while vTv Therapeutics granted options for 2,500 shares to support its type 1 diabetes program. Health Catalyst made the largest grant—2,747,385 restricted stock units to newly appointed CEO Simeon Kohl, who also purchased 59,000 shares on the open market at $1.79 per share.
All three companies used Nasdaq Listing Rule 5635(c)(4), which permits inducement awards to new employees or those returning after a bona fide employment gap. The grants reflect ongoing hiring efforts as these companies advance clinical programs and leadership transitions.
EyePoint and vTv Grant Standard Four-Year Options
EyePoint Pharmaceuticals granted stock options outside its existing 2023 Long-Term Incentive Plan. The new employee received options to purchase 3,000 shares, vesting 25% after one year, then equally over the following 36 months if employment continues. SEC filings show the option term extends 10 years from grant.
vTv Therapeutics followed the same structure with 2,500 options under its 2026 Inducement Plan. The award vests 25% at the one-year mark, then in quarterly increments over the next three years. Both grants were deemed material to candidates' decisions to join each company.
Health Catalyst's Larger CEO Equity Package
Health Catalyst granted CEO Simeon Kohl 2,747,385 restricted stock units, far exceeding the options grants at peer companies. According to company filings, 915,975 units vest after one year, with the remaining 1,831,410 vesting in eight equal quarterly installments over two years, contingent on continued service.
Kohl also made open-market purchases on September 11 and 14, 2026, buying 59,000 shares at a weighted average price of $1.787188 per share. His personal investment signals confidence in the health IT firm's direction.
vTv's Type 1 Diabetes Drug Advances in Testing
vTv Therapeutics is advancing cadisegliatin, described as a liver-selective glucokinase activator. In nonclinical studies, the drug increases glucokinase activity without requiring insulin. vTv reports the company is testing cadisegliatin in a U.S. Phase 3 trial as a potential first-in-class oral adjunctive treatment for type 1 diabetes.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
83
Reach
98
A
AnonymousAuthor
